Company intelligence / Profile preview
Imunexus
Melbourne, Victoria, Australiaimunexus.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Imunexus is developing a pipeline of preclinical-stage bispecific antibodies and enzymes using its proprietary imunexinTM platform. The lead assets target serious indications such as small cell lung cancer, rare pediatric diseases, and multiple sclerosis. No clinical results have been reported yet; all programs are at the preclinical stage.
- Therapeutic areas
- RheumatologyRare DiseasesNeurologyOncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyEnzyme replacement therapyBiological products (general)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Baker Heart and Diabetes Institute (neuropathologies research collaboration)Mesoblast Ltd. (“up to five next-gen mesenchymal stem cell therapies” partnership)
Beyond the preview
Go deeper on Imunexus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imunexus.